PL2401270T3 - Pochodne pirazolu stosowane jako antagoniści receptora CCR4 - Google Patents

Pochodne pirazolu stosowane jako antagoniści receptora CCR4

Info

Publication number
PL2401270T3
PL2401270T3 PL10705594T PL10705594T PL2401270T3 PL 2401270 T3 PL2401270 T3 PL 2401270T3 PL 10705594 T PL10705594 T PL 10705594T PL 10705594 T PL10705594 T PL 10705594T PL 2401270 T3 PL2401270 T3 PL 2401270T3
Authority
PL
Poland
Prior art keywords
receptor antagonists
pyrazole derivatives
derivatives used
ccr4 receptor
ccr4
Prior art date
Application number
PL10705594T
Other languages
English (en)
Inventor
Heather Hobbs
Simon Teanby Hodgson
Yannick Maurice Lacroix
Deborah Needham
Nigel James Parr
Panayiotis Alexandrou Procopiou
Timothy John Ritchie
Michael David Woodrow
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PL2401270T3 publication Critical patent/PL2401270T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL10705594T 2009-02-26 2010-02-24 Pochodne pirazolu stosowane jako antagoniści receptora CCR4 PL2401270T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15570209P 2009-02-26 2009-02-26
EP10705594.9A EP2401270B1 (en) 2009-02-26 2010-02-24 Pyrazole derivatives used as ccr4 receptor antagonists
PCT/EP2010/052307 WO2010097395A1 (en) 2009-02-26 2010-02-24 Pyrazole derivatives used as ccr4 receptor antagonists

Publications (1)

Publication Number Publication Date
PL2401270T3 true PL2401270T3 (pl) 2014-03-31

Family

ID=42110309

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10705594T PL2401270T3 (pl) 2009-02-26 2010-02-24 Pochodne pirazolu stosowane jako antagoniści receptora CCR4

Country Status (30)

Country Link
US (3) US8357716B2 (pl)
EP (1) EP2401270B1 (pl)
JP (1) JP5520969B2 (pl)
KR (1) KR20110128896A (pl)
CN (1) CN102388039B (pl)
AR (1) AR075594A1 (pl)
AU (2) AU2010217629A1 (pl)
BR (1) BRPI1013396A2 (pl)
CA (1) CA2753337A1 (pl)
CL (1) CL2011002103A1 (pl)
CO (1) CO6420342A2 (pl)
DK (1) DK2401270T3 (pl)
DO (1) DOP2011000272A (pl)
EA (1) EA021740B1 (pl)
ES (1) ES2439773T3 (pl)
HR (1) HRP20131174T1 (pl)
IL (1) IL214655A0 (pl)
MA (1) MA33132B1 (pl)
MX (1) MX2011008972A (pl)
NZ (1) NZ594641A (pl)
PE (1) PE20120307A1 (pl)
PL (1) PL2401270T3 (pl)
PT (1) PT2401270E (pl)
RS (1) RS53133B (pl)
SG (1) SG173768A1 (pl)
SI (1) SI2401270T1 (pl)
SM (1) SMT201400001B (pl)
TW (1) TW201041879A (pl)
UY (1) UY32464A (pl)
WO (1) WO2010097395A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2575816B2 (ja) 1988-06-13 1997-01-29 田中貴金属工業株式会社 粉末等の送り方法
AR068121A1 (es) 2007-08-31 2009-11-04 Eisai R&D Man Co Ltd Compuestos multiciclicos para tratar enfermedades neurodegenerativas
RU2515976C2 (ru) 2009-02-26 2014-05-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Азотсодержащие конденсированные гетероциклические соединения и их применение в качестве ингибиторов продукции бета-амилоида
BRPI1007883A2 (pt) 2009-02-26 2016-02-23 Eisai R&D Man Co Ltd sal, e, cristal.
US8729260B2 (en) * 2010-05-19 2014-05-20 Savior Lifetec Corporation Process for the preparation of carbapenem using cabapenem intermediates and recovery of cabapenem
WO2012025473A1 (en) * 2010-08-24 2012-03-01 Glaxo Group Limited Cc.chemokine receptor 4 antagonists
WO2015127125A1 (en) * 2014-02-20 2015-08-27 Cornell University Compounds and methods for inhibiting fascin
ES2925564T3 (es) * 2016-07-29 2022-10-18 Rapt Therapeutics Inc Derivados de azetidina tal como moduladores de receptores de quimiocinas y usos de los mismos
WO2018049271A1 (en) 2016-09-09 2018-03-15 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
JOP20190192A1 (ar) * 2017-03-01 2019-08-08 Glaxosmithkline Ip No 2 Ltd مشتقات بيرازول بوصفها مثبطات برومودومين
WO2018187509A1 (en) 2017-04-04 2018-10-11 Flx Bio, Inc. Heterocyclic compounds as chemokine receptor modulators
KR102615821B1 (ko) * 2017-04-11 2023-12-21 선샤인 레이크 파르마 컴퍼니 리미티드 불소-치환된 인다졸 화합물 및 이의 용도
AU2018360766B2 (en) 2017-11-06 2024-09-19 Rapt Therapeutics, Inc. Anticancer agents
CN110028501B (zh) * 2018-01-12 2022-02-22 迈德欣国际有限公司 化合物及其制备方法和用途
US10683280B2 (en) 2018-01-26 2020-06-16 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof
CN113893220A (zh) * 2020-07-07 2022-01-07 迈德欣国际有限公司 鼻粘膜给药剂型和其应用
CA3255429A1 (en) 2022-04-06 2023-10-12 Rapt Therapeutics, Inc. Chemokine Receptor Modulators and Their Uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2848554A1 (fr) * 2002-12-12 2004-06-18 Aventis Pharma Sa Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
RU2339624C2 (ru) 2002-12-12 2008-11-27 Авентис Фарма С.А. Производные аминоиндазолов и их применение в качестве ингибиторов киназ
SE0301650D0 (sv) * 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer

Also Published As

Publication number Publication date
US8507543B2 (en) 2013-08-13
EA201190142A1 (ru) 2012-05-30
MX2011008972A (es) 2011-12-14
JP2012518673A (ja) 2012-08-16
US20130030031A1 (en) 2013-01-31
ES2439773T3 (es) 2014-01-24
PT2401270E (pt) 2014-01-20
EA021740B1 (ru) 2015-08-31
RS53133B (sr) 2014-06-30
EP2401270A1 (en) 2012-01-04
SG173768A1 (en) 2011-09-29
HK1159621A1 (en) 2012-08-03
CN102388039A (zh) 2012-03-21
EP2401270B1 (en) 2013-10-16
CN102388039B (zh) 2015-07-15
US8357716B2 (en) 2013-01-22
WO2010097395A1 (en) 2010-09-02
UY32464A (es) 2010-09-30
US20120015932A1 (en) 2012-01-19
US8304446B2 (en) 2012-11-06
MA33132B1 (fr) 2012-03-01
IL214655A0 (en) 2011-09-27
SI2401270T1 (sl) 2014-01-31
US20100216860A1 (en) 2010-08-26
CA2753337A1 (en) 2010-09-02
PE20120307A1 (es) 2012-04-04
DOP2011000272A (es) 2011-12-31
AU2016203684A1 (en) 2016-06-23
CL2011002103A1 (es) 2012-02-24
HRP20131174T1 (hr) 2014-01-17
BRPI1013396A2 (pt) 2016-03-29
TW201041879A (en) 2010-12-01
CO6420342A2 (es) 2012-04-16
DK2401270T3 (da) 2014-01-13
SMT201400001B (it) 2014-03-07
KR20110128896A (ko) 2011-11-30
AR075594A1 (es) 2011-04-20
JP5520969B2 (ja) 2014-06-11
NZ594641A (en) 2013-03-28
AU2010217629A1 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
IL214655A0 (en) Pyrazole derivatives used as ccr4 receptor antagonists
IL202657A0 (en) Imidazole derivatives as ccr2 receptor antagonists
IL205665A0 (en) Heteroaryl derivatives as orexin receptor antagonists
IL200804A0 (en) Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
IL201112A0 (en) Thiazolidine derivatives as orexin receptor antagonists
IL208355A0 (en) Heterocyclic copmpounds as adenosine receptor antagonist
IL201620A0 (en) Quinoline-carboxamide derivatives as p2y12 antagonists
ZA201006104B (en) Substituted xanthine derivatives
IL215690A0 (en) Thiazole derivatives and their use as p2y12 receptor antagonists
IL207846A0 (en) Arylsulfonyl pyrazoline carboxaidine derivatives as 5-ht6 antagonists
IL209264A0 (en) Heteroaromatic monoamides as orexinin receptor antagonists
IL213869A0 (en) Quinazolinone derivatives useful as vanilloid antagonists
IL213982A0 (en) Piperidine derivatives as nk3 receptor antagonists
IL209126A0 (en) Quinuclidine derivatives as muscarinic m3 receptor antagonists
EP2370425A4 (en) IMIDAZOLE DERIVATIVES CONDENSED AS TRPV3 ANTAGONISTS
IL217759A0 (en) Pyrrolidine derivatives as nk3 receptor antagonists
IL207577A0 (en) Pyrrolidine ether derivatives as nk3 receptor antagonists
IL209266A0 (en) Pyrrolidine derivatives as nk2 receptor antagonists
IL220554A (en) History of aminoalkylpyrimidine as histamine receptor antagonists 4h
EP2367810A4 (en) CHROMENONE DERIVATIVES AS TRPV3 ANTAGONISTS
IL213763A0 (en) Pyrrolidine derivatives as nk3 receptor antagonists
IL210927A0 (en) 6-substituted benzoxazines as 5-ht-5a receptor antagonists
IL213769A0 (en) Piperidine derivatives as nk3 receptor antagonists
IL207438A0 (en) 2-aminoquinolines as 5-ht5a receptor antagonists
ZA200809977B (en) Benzimidazole derivatives which are to be used as antagonist for the CB1 receptor